Financials

Financials in One Page

Cigna is a $274.9B revenue health-services platform whose growth is mostly coming from Evernorth pharmacy and specialty services, not from a widening margin structure. The company earns thin operating margins because pharmacy-benefit and managed-care revenue carries high pass-through cost, but it converts earnings into cash: FY2025 free cash flow was $7.8B, or 1.24x reported net income. The balance sheet is usable rather than pristine, with net debt near 2.0x EBITDA and large goodwill/intangibles from prior deals. At the latest local price of $284.04, the stock trades at about 9.4x management's 2026 adjusted EPS outlook, reflecting durable cash flow offset by Evernorth client/PBM margin pressure. The single financial metric that matters most right now is Evernorth pre-tax margin, especially whether Pharmacy Benefit Services margin pressure stabilizes.

The local rankings file with Quality Score and Fair Value was not present, so this tab relies on reported financials, management outlook, price history, and peer financial data.

Revenue, Margins, and Earnings Power

Revenue is the amount billed for premiums, pharmacy services, fees, and related services. Operating income is profit after medical, pharmacy, and selling/general costs but before interest and taxes; it is the cleanest first read on core earnings power. Cigna's size changed permanently after the Express Scripts deal, and since 2019 the question has been whether the larger revenue base can produce more profit dollars without margin leakage.

Investor question: is growth translating into operating income?

The chart shows the basic underwriting point: Cigna is not a high-margin healthcare compounder. It is a scale platform where revenue growth can be impressive while operating income moves much more slowly. FY2025 revenue rose 11%, but operating income declined slightly to $9.2B, so the investor should focus on profit dollars, not headline sales.

Investor question: are margins improving, peaking, normalizing, or deteriorating?

Gross margin fell from roughly 16% after the Express Scripts step-up to 9.3% in FY2025, showing how much low-spread pharmacy revenue now dominates the income statement. Operating margin at 3.3% is acceptable for managed care and PBM economics, but it leaves little room for pricing mistakes, medical-cost surprises, or large-client concessions.

Investor question: what does the most recent quarterly trajectory say?

Q1 FY2026 revenue growth slowed to 4.6% after the divestiture of Medicare-related businesses and tougher comparisons, but operating margin improved to 3.4%. That is a constructive mix signal: the company can shrink or exit lower-return revenue and still grow adjusted earnings if medical cost and Evernorth margins behave.

Cash Flow and Earnings Quality

Free cash flow means cash generated after operating needs and capital expenditures. For Cigna, free cash flow is the reality check on GAAP earnings because medical costs payable, pharmacy receivables/payables, acquisitions, investment gains/losses, and acquired-intangible amortization can all make net income noisy.

Investor question: do reported earnings become cash?

Cigna's earnings quality is better than the low net margin implies. Since 2019, operating cash flow has exceeded net income every year, and FY2025 free cash flow of $7.8B covered net income by about 1.24x. That supports dividends, buybacks, and debt service even when GAAP earnings are hit by investment losses or special items.

Investor question: is the free-cash-flow margin durable?

The cash-flow margin is modest because Cigna's revenue base includes large pass-through dollars, but positive free cash flow has been dependable. The decline from 5.0% in 2023 to 2.8% in 2025 is worth watching: it means the stock's cash support depends more on absolute dollar stability than on margin expansion.

Investor question: what distorts cash flow?

Balance Sheet and Financial Resilience

Net debt is total debt less cash. Net debt divided by EBITDA, a proxy for recurring operating cash earnings before interest, taxes, depreciation and amortization, tells how many years of EBITDA would theoretically repay debt. Cigna's balance sheet adds some risk because goodwill and intangibles are high, but the cash flow profile gives it refinancing and capital-return flexibility.

Investor question: is leverage getting better or worse?

Total debt was $31.5B at FY2025, against $7.7B of cash. Net debt of $23.8B is not trivial, but it is manageable against $9.6B of operating cash flow and $12.0B of EBITDA. The company is not balance-sheet constrained, but it also does not have the net-cash optionality of an asset-light compounder.

Investor question: is interest burden a constraint?

Interest coverage, EBIT divided by interest expense, was 6.5x in FY2025. That is enough cushion for a stable managed-care and PBM platform, but not so high that leverage is irrelevant. Management's capital allocation should keep debt reduction in the conversation when buybacks compete with reinvestment.

Investor question: what are the balance-sheet pressure points?

Returns, Reinvestment, and Capital Allocation

Return on invested capital, or ROIC, measures profit after tax relative to the capital required to run the business. Return on equity, or ROE, measures profit relative to book equity. Cigna's ROE is respectable, but ROIC is modest because the company carries a large acquired asset base and operates in thin-margin health-services markets.

Investor question: does Cigna earn attractive returns on capital?

FY2025 ROE of 15.1% is solid, but ROIC of 5.7% is not a moat-like return. The value creation case therefore depends on steady cash generation, disciplined capital returns, and mix improvement inside Evernorth and Cigna Healthcare rather than unusually high reinvestment economics.

Investor question: where does the cash go?

Management is primarily returning excess cash rather than reinvesting heavily in physical assets. That fits the business model. The judgment on buybacks is mixed: repurchasing stock around low forward earnings multiples is accretive only if Evernorth profit pressure does not reset the earnings base lower.

Investor question: are buybacks improving per-share economics?

Diluted shares fell from 379.8M in 2019 to 268.6M in 2025, a 29% reduction. That is a real per-share tailwind and explains why adjusted EPS can compound faster than operating income, but it also means the earnings algorithm leans on continued cash generation and a reasonable stock price for repurchases.

Segment and Unit Economics

Cigna reports two main operating platforms. Evernorth Health Services includes Pharmacy Benefit Services and Specialty and Care Services; it is the revenue engine. Cigna Healthcare includes U.S. Healthcare and International Health; it is smaller after the Medicare-related divestiture but more directly exposed to medical-cost ratio, or MCR, which is medical costs divided by premiums. Adjusted revenue and adjusted income are management measures that exclude items such as investment effects, acquired-intangible amortization, and special items to show underlying segment trends; they are useful, but they are not a substitute for reported cash flow.

Investor question: which segment carries the economics?

Evernorth generated $235.0B of FY2025 adjusted revenue before corporate/elimination effects, about five times Cigna Healthcare's $47.2B. That explains why small changes in Evernorth economics matter so much even if Cigna Healthcare receives more attention when medical costs move.

Investor question: where are profit dollars produced?

The segment read-through is nuanced. Evernorth is the scale and cash engine, but its low margin means client-renewal economics and rebate-model transitions matter. Cigna Healthcare is smaller but has higher segment margins and produced a strong Q1 FY2026 margin after the Medicare-related divestiture.

Valuation and Market Expectations

Price-to-earnings, or P/E, is the stock price divided by earnings per share. For Cigna, P/E and P/FCF are the most useful first-pass multiples because the business produces recurring earnings and cash flow; price-to-book is less useful because goodwill and acquired intangibles dominate book capital.

Investor question: is the current valuation low relative to Cigna's own history?

The stock screens inexpensive on earnings: the latest price implies about 9.4x management's 2026 adjusted EPS outlook of at least $30.35, versus a 2016-2025 average reported P/E near 16.6x. The cash-flow multiple is less dramatic, around 9.6x FY2025 FCF at the latest price, because Cigna has usually traded at a high-single-digit to low-teens P/FCF. The discount is therefore a judgment on durability, not a simple mispricing.

Investor question: what does the current price imply under simple earnings cases?

The valuation is low with a reason. Cigna does not need a heroic multiple for acceptable scenario math, but it does need investors to believe that Evernorth can absorb rebate-free pricing and large-client economics without a structural profit reset, while Cigna Healthcare keeps MCR under control.

Peer Financial Comparison

The peer table uses FY2025 local ratios and market-data snapshots rather than current intraday market caps. It is for relative financial context; percentage fields are stored as decimals, so the table formats them as percentages.

Investor question: is Cigna's discount deserved relative to peers?

Cigna deserves to trade at a discount to UnitedHealth because UnitedHealth has historically earned higher operating margins and a broader care-delivery/services mix. The gap versus Elevance is less obvious: Cigna has similar growth, better cash conversion, and a lower P/E, but more Evernorth-specific PBM margin debate. Relative to CVS, Humana, and Centene, Cigna's cash conversion and balance-sheet profile look stronger, so the discount is mostly about regulatory/client pricing risk rather than weak financial quality.

What to Watch in the Financials

The financials confirm that Cigna is a cash-generative, shareholder-return-oriented health-services company with manageable leverage and a low valuation. They contradict any simple "revenue growth equals value creation" story because margins are thin, ROIC is only mid-single-digit, and Evernorth's enormous revenue base can grow while profit margins compress. The first metric to watch next quarter is whether Evernorth's pre-tax margin stabilizes after the Q1 FY2026 decline in Pharmacy Benefit Services profit.

The first financial metric to watch is… Evernorth pre-tax margin.